Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

British Journal of Cancer

Volumn 88, Issue 9, 2003, Pages 1335-1338

  Zekri, J M ^a   Hough, R E ^b   Davies, J M ^c   Molife, R ^d   Hancock, B W ^a   Lorigan, P C ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Docetaxel; Hodgkin's disease; Non Hodgkin's lymphoma

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GRANISETRON;

ADULT; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; INFUSION; LYMPHOMA; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD CELL COUNT; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038325691     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600914     Document Type: Article

References (17)

1. Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos M, Peterson BA (1997) Phase II trial of Docetaxel in non-Hodgkin's lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 15(10): 3275-3279
2. Crown J (1999) Phase III randomized trials of Docetaxel in patients with metastatic breast cancer. Semin Oncol 26(3, Suppl 8): 33-38
3. El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW (2000) VEDex (vincristine, epirubicin, dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma. Int J Oncol 16: 777-782
4. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalmen L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of Docetaxel versus Vinorelbine or Ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18(12): 2354-2362.
5. Gandara DR, Edelman MJ, Lau D (1999) Emerging role of Docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol 26(3, Suppl 10): 3-7
6. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 15; 57(2): 229-233
7. Hopfinger G, Heinz R, Pfeilstocker M, Schlogl E, Waldner R, Pittermann E (1996) Paclitaxel in the salvage treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Ann Oncol 7: 423-425
8. Hortobagyi GN (1999) Recent progress in the clinical development of Docetaxel (Taxotere). Semin Oncol 26(3, Suppl 9): 32-36
9. Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5 (Suppl 6): S3-S6.
10. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (2001) Combination chemotherapy with Carboplatin and Docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 19(7): 1901-1905
11. Ringel I, Horwitz SB (1991) Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 20; 83(4): 288-291
12. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-a phase II single-center study. J Clin Oncol 17(4): 1127-1131
13. Shamash J, Lee SM, Radford JA, Rohatiner AZ, Chang J, Morgenster GR, Scarffe JH, Deakin DP, Lister TA (2000): Patterns of relapse and subsequent management following high dose chemotherapy with autologus haematopoietic supporting relapsed or refractory Hodgkin's lymphoma: a two centre study. Ann Oncol 11(6): 715-719
14. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul J, Reed NS, Kaye SB (2001) Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 84(2): 170-178
15. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, Wittes RE (1995) Phase II study of Paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13(2): 381-386
16. Younes A, Ayoub J, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F (1997) Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haem 96: 328-332
17. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Sammuels BI, Palmer JL, Cabanilla F (2001) Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 12: 923-927